TITLE

Sen. Kennedy aims at drug marketing

AUTHOR(S)
Winters, Patricia; Freeman, Laurie
PUB. DATE
August 1990
SOURCE
Advertising Age;8/6/1990, Vol. 61 Issue 32, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on an investigation conducted by Senator Edward Kennedy on the marketing practices of the prescription drug industry in the United States. Kennedy sent letters to the nation's top pharmaceutical companies including Bristol-Myers Squibb Co., Pfizer and Warner-Lambert Co. requesting information about a variety of promotional practices ranging from advertising to the use of seminars and non-traditional media such as video news releases.
ACCESSION #
10484694

 

Related Articles

  • Drug Producers Continue To Record Strong Results. Mirasol, Feliza // Chemical Market Reporter;10/25/1999, Vol. 256 Issue 17, p5 

    Provides information on the increase of third quarter earnings of drug manufacturers in the U.S. in 1999. Warner-Lambert Co.; Pfizer Inc.; Pfizer Inc.; Bristol-Myers Squibb Co.

  • Drug wars escalate as 3 accounts go into play. Goetzl, David; Linnett, Richard // Advertising Age;9/18/2000, Vol. 71 Issue 39, Preceding p1 

    Reports that advertising accounts for two established cholesterol-lowering drugs and one whose availability is pending are in review. A shift in the status quo about to be experienced in the marketing of these drugs, known as statins; The existing drugs offered by Bristol-Myers Squibb Co. and...

  • BMS ups DTC to fend off generic Plavix. Iskowitz, Marc // Medical Marketing & Media;Nov2006, Vol. 41 Issue 11, p28 

    The article reports on the plan of Bristol-Myers Squibb Co. to expand the direct-to-consumer advertising for its Plavix in the U.S. The move is intended to counter the impact of the launching of its generic. Lamberto Andreotti, executive vice president and president, claims that the campaign...

  • Pharma: Other News To Note.  // BioWorld Today;12/27/2012, Vol. 23 Issue 249, p8 

    This section offers news briefs on the pharmaceutical sector including the approval received by Bristol-Myers Squibb Co. and Pfizer Inc. from the Japanese Ministry of Health, Labor, and Welfare for Eliquis, marketing authorization application submitted by Otsuka Pharmaceutical and H. Lundbeck...

  • Bristol-Myers and Pfizer report robust fourth quarter results in pharmaceuticals. MIRASOL, FELIZA // Chemical Market Reporter;01/25/99, Vol. 255 Issue 4, p4 

    Reports on drug manufacturers that experienced growth in the fourth quarter of 1998. Pfizer's total revenues; Bristol-Myers's earnings; Total worldwide sales of glucophage, an oral medication for the treatment of type-2 diabetes.

  • Sizing Up Big Pharma's Manufacturing Investment Strategies. Van Arnum, Patricia // Pharmaceutical Technology Europe;Aug2013, Vol. 25 Issue 8, p20 

    The article focuses on the trends of emerging markets of pharmaceutical companies across the world. It informs that Pfizer Inc. is investing 130 million dollars in two Irish manufacturing sites including the Grange Castle site, Dublin and the Ringaskiddy site, Cork. Bristol-Myers Squibb Co. is...

  • Meeting and event growth fuels drug industry promotion.  // Medical Marketing & Media;Dec98, Vol. 33 Issue 12, p21 

    Reports on the growth in promotional spending for pharmaceutical meetings and events in the second quarter of 1998. Total promotional spending reported; Products that led Pfizer's promotional spending activity; Rank of Bristol-Myers Squibb in total promotional spending.

  • BMS pledges DTC ban for all new drugs. Arnold, Matthew // Medical Marketing & Media;Jul2005, Vol. 40 Issue 7, p9 

    Reports that Bristol-Myers Squibb has vowed not to run branded TV, radio or print ads on new drugs for the 12 months following their launch, as part of its company code on DTC communications in the U.S. Focus on professional advertisements and medical education.

  • Spin Doctors. Egan, Mary Ellen // Forbes Global;11/29/2004, Vol. 7 Issue 21, p44 

    Presents information on strategies employed by drug companies to fight for their reputations. Argument of GlaxoSmithKline regarding the cost of medication; Drug discount program offered by Pfizer to deflect criticism; Involvement of Tour de France winner Lance Armstrong in a program launched by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics